MicroProbe Corp., a private oligonucleotide company based inBothell, Wash., announced that it had received a $50,000 PhaseI small business innovation research (SBIR) grant from theNational Institutes of Health to develop DNA probe-basedgenetic tests for type I insulin-dependent diabetes and forrheumatoid arthritis. The grant will go toward showing thefeasibility for direct detection of a specific gene associated witheach disease, said R. Michael Gendreau, vice president of R&D ofthe MicroProbe Diagnostics Division.

This award brings the total federal support for MicroProbe'sR&D programs to nearly $6 million.

(c) 1997 American Health Consultants. All rights reserved.